Regeneron Pharmaceuticals Aktie
543,20
EUR
-5,70
EUR
-1,04
%
619,35
USD
-4,11
USD
-0,66
%
Regeneron Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Regeneron Pharmaceuticals Aktie Analyse
| 20.10.17 | Regeneron Pharmaceuticals Underweight | Barclays Capital | |
| 01.08.17 | Regeneron Pharmaceuticals Underperform | Robert W. Baird & Co. Incorporated | |
| 07.11.16 | Regeneron Pharmaceuticals Sell | Chardan Capital Markets | |
| 16.03.16 | Regeneron Pharmaceuticals Sell | Chardan Capital Markets | |
| 25.01.16 | Regeneron Pharmaceuticals Sell | Chardan Capital Markets | |
| 05.08.15 | Regeneron Pharmaceuticals Sell | UBS AG | |
| 11.01.05 | Regeneron Pharmaceuticals Sell | Banc of America Sec. |
Werbung
Werbung